Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8558, USA.
Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Yale School of Medicine, Yale University, 300 Cedar Street TAC441S, New Haven, CT 06520-8057, USA.
Clin Chest Med. 2021 Jun;42(2):357-364. doi: 10.1016/j.ccm.2021.03.011.
Management of patients with interstitial lung disease (ILD) requires accurate classification. However, this process relies on subjective interpretation of nonspecific and overlapping clinical features that could hamper clinical care. The development and implementation of objective biomarkers reflective of specific disease states could facilitate precision-based approaches based on patient-level biology to improve the health of ILD patients. Omics-based studies allow for the seemingly unbiased and highly efficient screening of candidate biomarkers and offer unprecedented opportunities for discovery. This review outlines representative major omics-based discoveries in a well-studied condition, idiopathic pulmonary fibrosis, to develop a roadmap to personalized medicine in ILD.
管理间质性肺疾病（ILD）患者需要进行准确的分类。然而，这一过程依赖于对非特异性和重叠的临床特征的主观解释，这可能会妨碍临床护理。开发和实施反映特定疾病状态的客观生物标志物，可以促进基于患者个体生物学的精准医疗方法，从而改善ILD 患者的健康。基于组学的研究允许对候选生物标志物进行看似无偏见且高效的筛选，并为发现提供前所未有的机会。本综述概述了在一个研究充分的疾病——特发性肺纤维化中，基于组学的重要发现，以制定ILD 个体化医学的路线图。
